{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T02:42:24Z","timestamp":1783651344584,"version":"3.55.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s00406-016-0736-z","type":"journal-article","created":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T06:48:53Z","timestamp":1475304533000},"page":"325-333","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Clinical response in a risperidone-medicated naturalistic sample: patients\u2019 characteristics and dose-dependent pharmacokinetic patterns"],"prefix":"10.1007","volume":"267","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4198-5160","authenticated-orcid":false,"given":"Michael","family":"Paulzen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekkehard","family":"Haen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Stegmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Unterecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hiemke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Gr\u00fcnder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Schoretsanitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,1]]},"reference":[{"key":"736_CR1","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0278-5846(02)00218-X","volume":"26","author":"N Aymard","year":"2002","unstructured":"Aymard N, Viala A, Clement MN, Jacquot M, Vacheron MN, Gauillard J, Caroli F (2002) Long-term pharmacoclinical follow-up in schizophrenic patients treated with risperidone. Plasma and red blood cell concentrations of risperidone and its 9-hydroxymetabolite and their relationship to whole blood serotonin and tryptophan, plasma homovanillic acid, 5-hydroxyindoleacetic acid, dihydroxyphenylethyleneglycol and clinical evaluations. Prog Neuropsychopharmacol Biol Psychiatry 26:975\u2013988","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"736_CR2","unstructured":"Bader W, Melchner D, Nonenmacher T, Haen E (2005) Determination of five commonly used antipsychotics in human serum by high performance-liquid chromatography (HPLC) and electrochemical detection. International meeting on pharmacovigilance in psychiatry, therapeutic drug monitoring and pharmacogenetics of psychotropic drugs, Lausanne, Switzerland, 2004. Abstract Pharmacopsychiatry 38:4"},{"key":"736_CR3","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00007691-199902000-00017","volume":"21","author":"AE Balant-Gorgia","year":"1999","unstructured":"Balant-Gorgia AE, Gex-Fabry M, Genet C, Balant LP (1999) Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors. Ther Drug Monit 21:105\u2013115","journal-title":"Ther Drug Monit"},{"key":"736_CR4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-2007-1014401","volume":"25","author":"M Beneke","year":"1992","unstructured":"Beneke M, Rasmus W (1992) \u201cClinical Global Impressions\u201d (ECDEU): some critical comments. Pharmacopsychiatry 25:171\u2013176","journal-title":"Pharmacopsychiatry"},{"key":"736_CR5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00007691-200502000-00019","volume":"27","author":"I Castberg","year":"2005","unstructured":"Castberg I, Spigset O (2005) Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service. Ther Drug Monit 27:103\u2013106","journal-title":"Ther Drug Monit"},{"key":"736_CR6","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1440-1819.2003.01212.x","volume":"58","author":"PS Chen","year":"2004","unstructured":"Chen PS, Yang YK, Su SF, Liao YC, Chang JW, Yeh TL (2004) Correlation between scores on Continuous Performance Test and plasma concentration for schizophrenic patients on risperidone. Psychiatry Clin Neurosci 58:168\u2013172","journal-title":"Psychiatry Clin Neurosci"},{"key":"736_CR7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40268-015-0092-x","volume":"15","author":"M Corena-Mcleod","year":"2015","unstructured":"Corena-Mcleod M (2015) Comparative Pharmacology of Risperidone and Paliperidone. Drugs R D 15:163\u2013174","journal-title":"Drugs R D"},{"key":"736_CR8","doi-asserted-by":"crossref","unstructured":"De Leon J (2015) The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part I: a summary of the current state for clinicians. Revista de Psiquiatr\u00eda y Salud Mental (English Edition)","DOI":"10.1016\/j.rpsmen.2015.04.006"},{"key":"736_CR9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4088\/JCP.v66n0103","volume":"66","author":"J Leon De","year":"2005","unstructured":"De Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ (2005) The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 66:15\u201327","journal-title":"J Clin Psychiatry"},{"key":"736_CR10","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.psc.2007.04.001","volume":"30","author":"H Elkis","year":"2007","unstructured":"Elkis H (2007) Treatment-resistant schizophrenia. Psychiatr Clin N Am 30:511\u2013533","journal-title":"Psychiatr Clin N Am"},{"key":"736_CR11","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0006-3223(03)00231-2","volume":"53","author":"M Fava","year":"2003","unstructured":"Fava M (2003) Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 53:649\u2013659","journal-title":"Biol Psychiatry"},{"key":"736_CR12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.euroneuro.2013.09.003","volume":"24","author":"A Gallini","year":"2014","unstructured":"Gallini A, Andrieu S, Donohue JM, Oumouhou N, Lapeyre-Mestre M, Gardette V (2014) Trends in use of antipsychotics in elderly patients with dementia: impact of national safety warnings. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 24:95\u2013104","journal-title":"Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol"},{"key":"736_CR13","doi-asserted-by":"crossref","unstructured":"Guy W (1976) ECDEU assessment manual for psychopharmacology, revised. DHEW publication no. ADM 76-338, National Institute of Mental Health, Rockville","DOI":"10.1037\/e591322011-001"},{"key":"736_CR14","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1055\/s-0031-1292489","volume":"44","author":"E Haen","year":"2011","unstructured":"Haen E (2011) Therapeutic drug monitoring in pharmacovigilance and pharmacotherapy safety. Pharmacopsychiatry 44:254\u2013258","journal-title":"Pharmacopsychiatry"},{"key":"736_CR15","first-page":"13","volume":"55","author":"J Heykants","year":"1994","unstructured":"Heykants J, Huang ML, Mannens G, Meuldermans W, Snoeck E, Van Beijsterveldt L, Van Peer A, Woestenborghs R (1994) The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 55:13\u201317","journal-title":"J Clin Psychiatry"},{"key":"736_CR16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","volume":"44","author":"C Hiemke","year":"2011","unstructured":"Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Grunder G, Haen E, Havemann-Reinecke U, Jaquenoud Sirot E, Kirchherr H, Laux G, Lutz UC, Messer T, Muller MJ, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgler R, Zernig G (2011) AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44:195\u2013235","journal-title":"Pharmacopsychiatry"},{"key":"736_CR17","unstructured":"ICH Expert Working Group (ed) (1996) Harmonised tripartite guideline, validation of analytical procedures: test and methodology. In: International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. http:\/\/www.ich.org\/products\/guidelines\/efficacy\/article\/efficacy-guidelines.html . Accessed 29 Sep 2016"},{"key":"736_CR18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00004850-200503000-00002","volume":"20","author":"S Kakihara","year":"2005","unstructured":"Kakihara S, Yoshimura R, Shinkai K, Matsumoto C, Goto M, Kaji K, Yamada Y, Ueda N, Ohmori O, Nakamura J (2005) Prediction of response to risperidone treatment with respect to plasma concentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6. Int Clin Psychopharmacol 20:71\u201378","journal-title":"Int Clin Psychopharmacol"},{"key":"736_CR19","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/JCP.0000000000000294","volume":"35","author":"SG Kang","year":"2015","unstructured":"Kang SG, Na KS, Lee HJ, Chee IS, Lee K, Lee J (2015) DRD2 genotypic and haplotype variation is associated with improvements in negative symptoms after 6\u00a0weeks\u2019 amisulpride treatment. J Clin Psychopharmacol 35:158\u2013162","journal-title":"J Clin Psychopharmacol"},{"key":"736_CR20","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/FTD.0b013e3181aa4780","volume":"31","author":"AM Lostia","year":"2009","unstructured":"Lostia AM, Mazzarini L, Pacchiarotti I, Lionetto L, De Rossi P, Sanna L, Sani G, Kotzalidis GD, Girardi P, Simmaco M, Tatarelli R (2009) Serum levels of risperidone and its metabolite, 9-hydroxyrisperidone: correlation between drug concentration and clinical response. Ther Drug Monit 31:475\u2013481","journal-title":"Ther Drug Monit"},{"key":"736_CR21","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/FTD.0000000000000251","volume":"38","author":"B Mannheimer","year":"2016","unstructured":"Mannheimer B, Haslemo T, Lindh JD, Eliasson E, Molden E (2016) Risperidone and venlafaxine metabolic ratios strongly predict a CYP2D6 poor metabolizing genotype. Ther Drug Monit 38:127\u2013134","journal-title":"Ther Drug Monit"},{"key":"736_CR22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0924-9338(00)00536-8","volume":"16","author":"MC Mauri","year":"2001","unstructured":"Mauri MC, Laini V, Boscati L, Rudelli R, Salvi V, Orlandi R, Papa P (2001) Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels. Eur Psychiatry J Assoc Eur Psychiatrists 16:57\u201363","journal-title":"Eur Psychiatry J Assoc Eur Psychiatrists"},{"key":"736_CR23","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00228-010-0812-7","volume":"66","author":"Y Nazirizadeh","year":"2010","unstructured":"Nazirizadeh Y, Vogel F, Bader W, Haen E, Pfuhlmann B, Gr\u00fcnder G, Paulzen M, Schwarz M, Zernig G, Hiemke C (2010) Serum concentrations of paliperidone versus risperidone and clinical effects. Eur J Clin Pharmacol 66:797\u2013803","journal-title":"Eur J Clin Pharmacol"},{"key":"736_CR24","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1007\/s00213-014-3515-4","volume":"231","author":"M Nikolac Perkovic","year":"2014","unstructured":"Nikolac Perkovic M, Nedic Erjavec G, Zivkovic M, Sagud M, Uzun S, Mihaljevic-Peles A, Kozumplik O, Muck-Seler D, Pivac N (2014) Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients. Psychopharmacology 231:3757\u20133764","journal-title":"Psychopharmacology"},{"key":"736_CR25","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2165\/00044011-200019040-00006","volume":"19","author":"P Odou","year":"2000","unstructured":"Odou P, Levron JC, Luyckx M, Brunet C, Robert H (2000) Risperidone drug monitoring: a useful clinical tool? Clin Drug Invest 19:283\u2013292","journal-title":"Clin Drug Invest"},{"key":"736_CR26","first-page":"142","volume":"76","author":"L Paul","year":"2009","unstructured":"Paul L, Musshoff F, Aebi B, Auw\u00e4rter V, Kr\u00e4mer T, Peters F, Skopp G, Aderjan R, Herbold M, Schmitt G (2009) Richtlinie der GTFCh zur Qualit\u00e4tssicherung bei forensisch-toxikologischen Untersuchungen. Toxichem Krimtech 76:142\u2013176","journal-title":"Toxichem Krimtech"},{"key":"736_CR27","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1177\/0269881116650390","volume":"30","author":"M Paulzen","year":"2016","unstructured":"Paulzen M, Haen E, Gr\u00fcnder G, Lammertz SE, Stegmann B, Schruers KR, Walther S, Schoretsanitis G (2016) Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients\u2013thinking of clinically relevant CYP2D6 interactions. J Psychopharmacol 30:803\u2013809","journal-title":"J Psychopharmacol"},{"key":"736_CR28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.psyneuen.2016.07.009","volume":"73","author":"M Paulzen","year":"2016","unstructured":"Paulzen M, Haen E, Stegmann B, Hiemke C, Gr\u00fcnder G, Lammertz SE, Schoretsanitis G (2016) Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; A pharmacokinetics-based hypothesis. Psychoneuroendocrinology 73:9\u201315","journal-title":"Psychoneuroendocrinology"},{"key":"736_CR29","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/01.pra.0000445247.54048.68","volume":"20","author":"SH Preskorn","year":"2014","unstructured":"Preskorn SH (2014) Therapeutic Drug Monitoring (TDM) in psychiatry (part I): why studies attempting to correlate drug concentration and antidepressant response don\u2019t work. Journal of Psychiatric Practice 20:133\u2013137","journal-title":"Journal of Psychiatric Practice"},{"key":"736_CR30","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/bcp.12312","volume":"77","author":"GP Reynolds","year":"2014","unstructured":"Reynolds GP, Mcgowan OO, Dalton CF (2014) Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms. Br J Clin Pharmacol 77:654\u2013672","journal-title":"Br J Clin Pharmacol"},{"key":"736_CR31","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00406-004-0556-4","volume":"255","author":"M Riedel","year":"2005","unstructured":"Riedel M, Schwarz MJ, Strassnig M, Spellmann I, Muller-Arends A, Weber K, Zach J, Muller N, Moller HJ (2005) Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci 255:261\u2013268","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"Suppl 16","key":"736_CR32","first-page":"10","volume":"62","author":"HA Sackeim","year":"2001","unstructured":"Sackeim HA (2001) The definition and meaning of treatment-resistant depression. J Clin Psychiatry 62(Suppl 16):10\u201317","journal-title":"J Clin Psychiatry"},{"key":"736_CR33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/YIC.0000000000000131","volume":"31","author":"G Schoretsanitis","year":"2016","unstructured":"Schoretsanitis G, Haen E, Hiemke C, Grunder G, Stegmann B, Schruers KR, Veselinovic T, Lammertz SE, Paulzen M (2016) Risperidone-induced extrapyramidal side effects: is the need for anticholinergics the consequence of high plasma concentrations? Int Clin Psychopharmacol 31:259\u2013264","journal-title":"Int Clin Psychopharmacol"},{"key":"736_CR34","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00228-016-2085-2","volume":"72","author":"G Schoretsanitis","year":"2016","unstructured":"Schoretsanitis G, Stegmann B, Hiemke C, Grunder G, Schruers KR, Walther S, Lammertz SE, Haen E, Paulzen M (2016) Pharmacokinetic patterns of risperidone-associated adverse drug reactions. Eur J Clin Pharmacol 72:1091\u20131098","journal-title":"Eur J Clin Pharmacol"},{"key":"736_CR35","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/FTD.0b013e3182126d83","volume":"33","author":"K Seto","year":"2011","unstructured":"Seto K, Dumontet J, Ensom MH (2011) Risperidone in schizophrenia: is there a role for therapeutic drug monitoring? Ther Drug Monit 33:275\u2013283","journal-title":"Ther Drug Monit"},{"key":"736_CR36","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.pnpbp.2014.02.006","volume":"51","author":"I Spellmann","year":"2014","unstructured":"Spellmann I, Rujescu D, Musil R, Meyerwas S, Giegling I, Genius J, Zill P, Dehning S, Cerovecki A, Seemuller F, Schennach R, Hartmann AM, Schafer M, Muller N, Moller HJ, Riedel M (2014) Pleckstrin homology domain containing 6 protein (PLEKHA6) polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 51:190\u2013195","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"Suppl 13","key":"736_CR37","first-page":"23","volume":"58","author":"ME Thase","year":"1997","unstructured":"Thase ME, Rush AJ (1997) When at first you don\u2019t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 58(Suppl 13):23\u201329","journal-title":"J Clin Psychiatry"},{"key":"736_CR38","unstructured":"US Food and Drug Administration (2001). Guidance for industry on biomedical method validation. http:\/\/www.fda.gov\/ucm\/groups\/fdagov-public\/@fdagov-drugs-gen\/documents\/document\/ucm070107.pdf . Accessed 18 Aug 2016"},{"key":"736_CR39","unstructured":"US Food and Drug Administration (2014). Drug development and drug interactions: table of substrates, inhibitors and inducers. http:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/DrugInteractionsLabeling\/ucm093664.htm . Accessed 18 Aug 2016"},{"key":"736_CR40","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/01.jcp.0000186242.26050.1e","volume":"25","author":"SK Verma","year":"2005","unstructured":"Verma SK, Tan CH, Chan YH, Chong SA (2005) Plasma risperidone levels and clinical response in patients with first-episode psychosis. J Clin Psychopharmacol 25:609\u2013611","journal-title":"J Clin Psychopharmacol"},{"key":"736_CR41","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/0269881107077357","volume":"21","author":"L Wang","year":"2007","unstructured":"Wang L, Yu L, Zhang AP, Fang C, Du J, Gu NF, Qin SY, Feng GY, Li XW, Xing QH, He L (2007) Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia. J Psychopharmacol 21:837\u2013842","journal-title":"J Psychopharmacol"},{"key":"736_CR42","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/JCP.0b013e318283963b","volume":"33","author":"Z Wei","year":"2013","unstructured":"Wei Z, Wang L, Yu T, Wang Y, Sun L, Wang T, Huo R, Li Y, Wu X, Qin S, Xu Y, Feng G, He L, Xing Q (2013) Histamine H4 receptor polymorphism: a potential predictor of risperidone efficacy. J Clin Psychopharmacol 33:221\u2013225","journal-title":"J Clin Psychopharmacol"},{"key":"736_CR43","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1177\/0091270009347867","volume":"50","author":"Q Xiang","year":"2010","unstructured":"Xiang Q, Zhao X, Zhou Y, Duan JL, Cui YM (2010) Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety. J Clin Pharmacol 50:659\u2013666","journal-title":"J Clin Pharmacol"},{"key":"736_CR44","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s11684-013-0249-3","volume":"7","author":"Q Xu","year":"2013","unstructured":"Xu Q, Wu X, Xiong Y, Xing Q, He L, Qin S (2013) Pharmacogenomics can improve antipsychotic treatment in schizophrenia. Front Med 7:180\u2013190","journal-title":"Front Med"},{"key":"736_CR45","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1177\/0269881109104849","volume":"24","author":"N Yasui-Furukori","year":"2010","unstructured":"Yasui-Furukori N, Saito M, Nakagami T, Furukori H, Suzuki A, Kondo T, Kaneko S (2010) Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients. J Psychopharmacol 24:987\u2013994","journal-title":"J Psychopharmacol"},{"key":"736_CR46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/bdi.12025","volume":"15","author":"LN Yatham","year":"2013","unstructured":"Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O\u2019Donovan C, Macqueen G, Mcintyre RS, Sharma V, Ravindran A, Young LT, Milev R, Bond DJ, Frey BN, Goldstein BI, Lafer B, Birmaher B, Ha K, Nolen WA, Berk M (2013) Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 15:1\u201344","journal-title":"Bipolar Disord"},{"key":"736_CR47","doi-asserted-by":"publisher","unstructured":"Zhou XP, Keitner GIP, Qin BM, Ravindran AVP, Bauer MP, Del Giovane CP, Zhao JP, Liu YM, Fang YP, Zhang YP, Xie P (2015) Atypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis. Int J Neuropsychopharmacol 18(11). doi: 10.1093\/ijnp\/pyv060","DOI":"10.1093\/ijnp\/pyv060"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-016-0736-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00406-016-0736-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-016-0736-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T01:39:20Z","timestamp":1568425160000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00406-016-0736-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,1]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["736"],"URL":"https:\/\/doi.org\/10.1007\/s00406-016-0736-z","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,1]]}}}